New & Noteworthy

May 2022

Positive 3CL Protease Inhibition In Vitro Data Against SARS-CoV-2 Variants

Todos Medical Ltd

Todos Medical announces that its subsidiary 3CL Pharma’s mechanism-based 3CL protease inhibitors Tollovir and Tollovid, which target the active site of the 3CL protease, showed robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC). Further, Tollovir and Tollovid showed inhibitory activity against the original wild-type SARS-CoV-2 strain, as well as the alpha, beta, delta, and gamma VOCs. The results showed IC50 binding affinity of less than 5 for Tollovid and less than 1 for Tollovir for each of the different SARS-CoV-2 strains.

Request More Information

Current Issue